Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis

Advances in Therapy

Volumn 27, Issue 10, 2010, Pages 743-755

  Hess, Gregory ^a,b   Hill, Jerrold W ^a   Raut, Monika K ^c   Fisher, Alan C ^c   Mody, Samir ^c   Schein, Jeff R ^c   Chen, Chi Chang ^a  

^a SDI   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Amoxicillin clavulanate; Antibiotic; Antimicrobial therapy; Azithromycin; Community acquired pneumonia; Fluoroquinolone; Levofloxacin; Macrolide; Penicillin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; ANTIINFECTIVE AGENT; OFLOXACIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED STATES; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; COMPARATIVE STUDY; INSURANCE; MIDDLE AGED; RISK FACTOR; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

EID: 79952118854     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0062-1     Document Type: Article

References (23)

1. Carbonara S, Monno L, Longo B, Angarano G. Community-acquired pneumonia. Curr Opin Pulm Med. 2009;15:261-273.
2. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. National Vital Statistics Report. 2009;57:1-134.
3. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. National Health Statistics Report. 2008;8:1-29.
4. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National hospital discharge survey. National Health Statistics Reports. 2008;5:1-20.
5. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009;(4):CD002109.
6. Niederman MS. Community-acquired pneumonia: the US perspective. Semin Respir Crit Care Med. 2009;30:179-188.
7. Niederman M. In the clinic. Community-acquired pneumonia. Ann Intern Med. 2009;151:ITC4-2-14.
8. Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest. 2007;132:1348-1355. (Pubitemid 47621012)
9. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004;164:502-508. (Pubitemid 38314445)
10. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59:960-965. (Pubitemid 39490781)
11. Garcia-Vidal C, Carratala J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med. 2009;30:154-160.
12. Monte SV, Paolini NM, Slazak EM, Schentag JJ, Paladino JJ. Costs of treating lower respiratory tract infections. Am J Manag Care. 2008;14:190-196. (Pubitemid 351501857)
13. Ortqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest. 1990;97:576-582. (Pubitemid 20095572)
14. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med. 2000;162:154-160. (Pubitemid 30469813)
15. Ye X, Sikirica V, Schein JR, et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia in an outpatient setting: a retrospective claims database analysis. Clin Ther. 2008;30:358-371. (Pubitemid 351474372)
16. Goldman LE, Vittinghoff E, Dudley RA. Quality of care in hospitals with a high percent of Medicaid patients. Medical Care. 2007;45:579-583.
17. File TM. The science of selecting antimicrobials for community-acquired pneumonia. J Manag Care Pharm. 2009;15:S5-S11.
18. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy. 2004;50:3-10. (Pubitemid 39179214)
19. Goto H, Shimada K, Ikemoto H, Oguri T. Study Group on Antimicrobial Susceptibility of Pathogens Isolated from Respiratory Infections. Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study. J Infect Chemother. 2009;15:347-360.
20. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009;15:1260-1264.
21. File RM Jr., Tan JS. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. Drugs. 2003;63:181-205. (Pubitemid 36143344)
22. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis. 2005;11:802-807. (Pubitemid 40720838)
23. Iannini PB, Paladino JA, Lavin B, Singer ME, Schentag JJ. A case series of macrolide treatment failures in community acquired pneumonia. J Chemother. 2007;19:536-545. (Pubitemid 350177965)